|
Study |
Design |
Population |
Outcomes |
Results |
Adjustments |
Comments |
|
|
|
|
|
FVC, but not FEV1, associated with self-report of oil-fire exposure |
|
use of modeled oil-fire exposures |
|
Ishoy et al., 1999b (Vol. 4) |
Cross-sectional, population-based, medical evaluation |
686 peace-keeping Danish deployed to Gulf War theater vs 231 nondeployed controls |
Shortness of breath; FVC; FEV1; peak flow |
14% vs 3.5% Percent of predicted: 100.7 vs 100.7, NS 95.6 vs 96.4, NS 94.0 vs 92.8, NS |
None |
Appropriate population-based controls but differential participation: 84% deployed vs 58% nondeployed; smoking histories similar in deployed and nondeployed |
|
Smith et al., 2006 (Update) |
Hospitalizations cohort study (cohort data from DMDC) |
Active-duty personnel with a single deployment to: Gulf War theater (n = 455,465); Southwest Asia peacekeeping mission, 1991-1998 (n = 249,047); Bosnia, 1995-1998 (n = 44,341) |
Postdeployment hospitalization events (1991-2000) for an ICD-9-CM diagnosis of respiratory disease (140-208), and for testicular cancer specifically |
Veterans of Bosnia compared to GWV: HR 0.73 (95% CI 0.63-0.84) Veterans of Southwest Asia compared to GWV: HR 1.08 (95% CI 1.00-1.16) |
Sex, age, marital status, pay grade, race/ethnicity, service branch, occupation, and predeployment hospitalization; time-dependent covariate to account for changing hospitalization methods, diagnostic criteria, and procedures |
Active-duty personnel only; hospitalizations at DoD facilities only |
|
Macfarlane et al., 2000, 2005 (Update) |
Cohort study |
2000: 53,462 UK GWVs vs 53,450 nondeployed UK veterans 2005: 51,753 UK GWVs and 50,808 nondeployed UK veterans |
Mortality (1991-1999/2004) due to diseases of the respiratory system |
2000: 3 deaths in GWVs compared to 3 deaths in control group, MRR 1.0 (95% CI 0.1-7.5) 2005: 9 deaths in GWVs compared to 6 deaths in control group, MRR 1.64 (95% CI 0.58-4.66) |
Matching by sex, age, branch, fitness for service |
|